Associations of Antimicrobial-Resistant Gram-Negative Bloodstream Infections with Outcomes among Hospitalized Pediatric Patients in the United States

Abstract

Objective The aim of this study was to assess the impact of pediatric antimicrobial-resistant gram-negative bloodstream infections (GNBSIs).

Methods A retrospective cohort study (2009–2016) was conducted using the Premier Healthcare Database among pediatric admissions with GNBSIs at hospitals reporting microbiology data. Infections for neonates and nonneonates were classified as multidrug resistance (MDR), resistant to one or two antibiotic drug classes (1–2DR), or susceptible.

Results Among 1,276 GNBSIs, 266 (20.8%) infections were 1–2DR and 23 (1.8%) MDR. Compared with susceptible GNBSIs, MDR nonneonates had higher mortality and higher costs, whereas 1–2DR neonates had longer stays and higher costs.

Conclusions Antimicrobial-resistant GNBSIs were associated with worse outcomes among pediatric hospitalized patients.

Keywords

antimicrobial resistance - bloodstream infections - pediatric

Publikationsverlauf

Eingereicht: 01. September 2020

Angenommen: 23. April 2021

Artikel online veröffentlicht:
28. Juli 2021

• References

• 1 Kadri SS, Adjemian J, Lai YL. et al; National Institutes of Health Antimicrobial Resistance Outcomes Research Initiative (NIH–ARORI). Difficult-to-treat resistance in gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents. Clin Infect Dis 2018; 67 (12) 1803-1814
• 2 Cassini A, Högberg LD, Plachouras D. et al; Burden of AMR Collaborative Group. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European economic area in 2015: a population-level modelling analysis. Lancet Infect Dis 2019; 19 (01) 56-66
• 3 Stone PW, Gupta A, Loughrey M. et al. Attributable costs and length of stay of an extended-spectrum beta-lactamase-producing Klebsiella pneumoniae outbreak in a neonatal intensive care unit. Infect Control Hosp Epidemiol 2003; 24 (08) 601-606
• 4 Schulman J, Dimand RJ, Lee HC, Duenas GV, Bennett MV, Gould JB. Neonatal intensive care unit antibiotic use. Pediatrics 2015; 135 (05) 826-833
• 5 Gerber JS, Newland JG, Coffin SE. et al. Variability in antibiotic use at children's hospitals. Pediatrics 2010; 126 (06) 1067-1073
• 6 Brogan TV, Thurm C, Hersh AL. et al. Variability in antibiotic use across PICUs. Pediatr Crit Care Med 2018; 19 (06) 519-527
• 7 Milstone AM, Bryant KA, Huskins WC, Zerr DM. The past, present, and future of healthcare-associated infection prevention in pediatrics: multidrug-resistant organisms. Infect Control Hosp Epidemiol 2010; 31 (Suppl. 01) S18-S21
• 8 Lake JG, Weiner LM, Milstone AM, Saiman L, Magill SS, See I. Pathogen distribution and antimicrobial resistance among pediatric healthcare-associated infections reported to the National Healthcare Safety Network, 2011-2014. Infect Control Hosp Epidemiol 2018; 39 (01) 1-11
• 9 Brandon M, Dowzicky MJ. Antimicrobial susceptibility among Gram-positive organisms collected from pediatric patients globally between 2004 and 2011: results from the Tigecycline Evaluation and Surveillance Trial. J Clin Microbiol 2013; 51 (07) 2371-2378
• 10 Logan LK, Bonomo RA. Metallo-β-lactamase (MBL)-producing Enterobacteriaceae in United States children. Open Forum Infect Dis 2016; 3 (02) ofw090
• 11 Logan LK, Renschler JP, Gandra S, Weinstein RA, Laxminarayan R. Centers for Disease Control, Prevention Epicenters Program. Carbapenem-resistant Enterobacteriaceae in children, United States, 1999-2012. Emerg Infect Dis 2015; 21 (11) 2014-2021
• 12 Logan LK, Braykov NP, Weinstein RA, Laxminarayan R. CDC Epicenters Prevention Program. Extended-Spectrum β-lactamase-producing and third-generation cephalosporin-resistant Enterobacteriaceae in children: trends in the United States, 1999-2011. J Pediatric Infect Dis Soc 2014; 3 (04) 320-328
• 13 Tamma PD, Robinson GL, Gerber JS. et al. Pediatric antimicrobial susceptibility trends across the United States. Infect Control Hosp Epidemiol 2013; 34 (12) 1244-1251
• 14 Logan LK, Gandra S, Trett A, Weinstein RA, Laxminarayan R. Acinetobacter baumannii resistance trends in children in the United States, 1999-2012. J Pediatric Infect Dis Soc 2019; 8 (02) 136-142
• 15 Li DX, Sick-Samuels AC, Suwantarat N, Same RG, Simner PJ, Tamma PD. Risk factors for extended-spectrum beta-lactamase-producing Enterobacteriaceae carriage upon pediatric intensive care unit admission. Infect Control Hosp Epidemiol 2018; 39 (01) 116-118
• 16 Meropol SB, Haupt AA, Debanne SM. Incidence and outcomes of infections caused by multidrug-resistant Enterobacteriaceae in children, 2007-2015. J Pediatric Infect Dis Soc 2018; 7 (01) 36-45
• 17 Sick AC, Tschudin-Sutter S, Turnbull AE, Weissman SJ, Tamma PD. Empiric combination therapy for gram-negative bacteremia. Pediatrics 2014; 133 (05) e1148-e1155
• 18 Mauldin PD, Salgado CD, Hansen IS, Durup DT, Bosso JA. Attributable hospital cost and length of stay associated with health care-associated infections caused by antibiotic-resistant gram-negative bacteria. Antimicrob Agents Chemother 2010; 54 (01) 109-115
• 19 Blaschke AJ, Korgenski EK, Daly JA, LaFleur B, Pavia AT, Byington CL. Extended-spectrum beta-lactamase-producing pathogens in a children's hospital: a 5-year experience. Am J Infect Control 2009; 37 (06) 435-441
• 20 Chiotos K, Tamma PD, Flett KB. et al. Increased 30-day mortality associated with carbapenem-resistant Enterobacteriaceae in children. Open Forum Infect Dis 2018; 5 (10) ofy222
• 21 Benner KW, Prabhakaran P, Lowros AS. Epidemiology of infections due to extended-spectrum Beta-lactamase-producing bacteria in a pediatric intensive care unit. J Pediatr Pharmacol Ther 2014; 19 (02) 83-90
• 22 Jhaveri R, Bronstein D, Sollod J, Kitchen C, Krogstad P. Outcome of infections with extended spectrum beta-lactamase producing organisms in children. J Pediatric Infect Dis Soc 2008; 3: 229-233
• 23 Logan LK, Meltzer LA, McAuley JB. et al; CDC Epicenters Prevention Program. Extended-spectrum β-lactamase-producing Enterobacteriaceae infections in children: a two-center case-case-control study of risk factors and outcomes in Chicago, Illinois. J Pediatric Infect Dis Soc 2014; 3 (04) 312-319
• 24 Zaoutis TE, Goyal M, Chu JH. et al. Risk factors for and outcomes of bloodstream infection caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in children. Pediatrics 2005; 115 (04) 942-949
• 25 Logan LK, Nguyen DC, Scaggs Huang FA. et al. A multi-centered case-case-control study of factors associated with Klebsiella pneumoniae Carbapenemase-producing Enterobacteriaceae infections in children and young adults. Pediatr Infect Dis J 2019; 38 (05) 490-495
• 26 Haas EJ, Zaoutis TE, Prasad P, Li M, Coffin SE. Risk factors and outcomes for vancomycin-resistant Enterococcus bloodstream infection in children. Infect Control Hosp Epidemiol 2010; 31: 1038-1042
• 27 Premier Healthcare Database. Premier Healthcare Database: Datat that Informs and Performs 2020.. Accessed May 12, 2021 at: https://learn.premierinc.com/white-papers/premier-healthcare-database-whitepaper
• 28 Spaulding AB, Watson D, Dreyfus J. et al. Epidemiology of bloodstream infections in hospitalized children in the United States, 2009–2016. Clin Infect Dis 2018
• 29 Feudtner C, Feinstein JA, Zhong W, Hall M, Dai D. Pediatric complex chronic conditions classification system version 2: updated for ICD-10 and complex medical technology dependence and transplantation. BMC Pediatr 2014; 14: 199
• 30 U.S. Bureau of Labor Statistics. Division of Consumer Prices and Price Index. Consumer Price Index-All Urban Consumers (Current Series) - U.S. Medical Care 2016. Accessed May 12, 2021 at: https://www.bls.gov/cpi/
• 31 Medernach RL, Logan LK. The growing threat of antibiotic resistance in children. Infect Dis Clin North Am 2018; 32 (01) 1-17
• 32 Tamma PD, Hsu AJ. Defining the role of novel β-lactam agents that target carbapenem-resistant gram-negative organisms. J Pediatric Infect Dis Soc 2019; 8 (03) 251-260